The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
License agreement signed with the Turkish pharmaceutical company TR-Pharm on the anti-rheumatic arthritis drug “iguratimod”
|October 13, 2015|
Fujifilm Group company Toyama Chemical Co., Ltd. (President Masuji Sugata; hereinafter Toyama Chemical) has signed a licensing agreement with TR-Pharm (President Tuygan Göker), a Turkey-based company developing, manufacturing and marketing pharmaceuticals, concerning Toyama Chemical’s rheumatoid arthritis drug “iguratimod” (Development Product Code: T-614) in this September.
Iguratimod is a drug for treating rheumatoid arthritis* jointly developed with Eisai Co., Ltd.,. It was approved for manufacturing and marketing in Japan on June 29, 2012, and launched in the domestic market in September of the same year. Iguratimod is an oral drug that underwent domestic clinical trials in combination with methotrexate (hereinafter MTX), the standard of care for rheumatoid arthritis, and became the first agent in Japan that demonstrated efficacy when administered in combination with MTX on rheumatoid arthritis patients who did not achieve satisfactory benefit with MTX alone. There is therefore high expectation for iguratimod as a drug that provides a new treatment option for rheumatoid arthritis and offers the choice of agents to be administered to patients according to their condition of rheumatoid arthritis.
The new licensing partner TR-Pharm is an affiliate of Russia’s powerful pharmaceutical company R-Pharm. TR-Pharm has been established as a development and manufacturing base for Turkey, Middle East and North Africa. TR-Pharm has over 10 agents in the development pipeline, focusing on the fields of oncology, virology and inflammatory diseases for business expansion.
Under the licensing agreement, Toyama Chemical provides TR-Pharm with the exclusive rights for developing, manufacturing and marketing iguratimod for the treatment of rheumatoid arthritis in Turkey, Middle East and North Africa, in exchange for a lump-sum payment and royalty.
Toyama Chemical, a subsidiary of FUJIFILM Holdings Corporation, specializes in pharmaceutical research and development, and strives to contribute to the further development of global health care through new drug development.
*In Japan, iguratimod is distributed and marketed by Taisho Toyama Pharmaceutical as Kolbet® Tablets 25mg and by Eisai Co., Ltd. as Careram® Tablets 25mg.
President: Tuygan Göker
Paid-in capital: 30 million euros
Number of employees: 13 (as of the end of September 2015)
Business description: Development, manufacturing and marketing of pharmaceuticals